母亲使用文拉法辛后的妊娠结局：一项前瞻性观察性对比队列研究。
Pregnancy outcomes following maternal venlafaxine use: A prospective observational comparative cohort study.
机构信息
UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK; Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
Institute of Cellular Medicine, Newcastle University, Newcastle, UK.
出版信息
Reprod Toxicol. 2019 Mar;84:108-113. doi: 10.1016/j.reprotox.2019.01.003. Epub 2019 Jan 11.
BACKGROUND
Venlafaxine is a serotonin noradrenaline reuptake inhibitor used to treat major depressive episodes and anxiety disorders. The primary aim of this study was to investigate spontaneous abortion risks following gestational exposure.
METHODS
This prospective observational comparative cohort study utilised data collected by the UK Teratology Information Service (UKTIS) between 1995 and 2018. The study sample included 281 venlafaxine exposed pregnancies matched to antidepressant unexposed (n = 1405) and SSRI exposed (n = 843) comparator groups.
RESULTS
After correction for variation in competing outcome rates and the stage of pregnancy at reporting, no statistically significant differences in the hazard of spontaneous abortion was observed following gestational venlafaxine use compared with either antidepressant unexposed (HR 1.28, 95% CI; 0.850-1.94) or SSRI exposed (HR 1.03, 95% CI; 0.681-1.57) pregnancies.
CONCLUSIONS
No conclusive evidence is provided from this study that venlafaxine increases the risk of adverse pregnancy or fetal outcomes.
背景
文拉法辛是一种用于治疗重度抑郁发作和焦虑症的 5-羟色胺和去甲肾上腺素再摄取抑制剂。本研究的主要目的是调查妊娠期暴露后文拉法辛的自然流产风险。
方法
这是一项前瞻性观察性对照队列研究，利用英国畸形信息服务处（UKTIS）在 1995 年至 2018 年期间收集的数据。研究样本包括 281 例文拉法辛暴露妊娠，与抗抑郁药未暴露（n=1405）和 SSRI 暴露（n=843）对照组相匹配。
结果
在纠正竞争结果发生率和报告时妊娠阶段的变化后，与抗抑郁药未暴露（HR 1.28，95%CI；0.850-1.94）或 SSRI 暴露（HR 1.03，95%CI；0.681-1.57）妊娠相比，妊娠期使用文拉法辛后自然流产的风险无统计学显著差异。
结论
本研究没有提供确凿的证据表明文拉法辛会增加不良妊娠或胎儿结局的风险。
Zotero 插件